Apollomics Announces Receipt of Nasdaq Delisting Notification, and Will Appeal to Retain

FOSTER CITY, CA, UNITED STATES, September 22, 2025 — Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the”Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced that the Company received a letter (the “Letter”) on September 18, 2025 fromthe Listing Qualifications Staff (the “Staff’) of The […]